Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by HighSkies2019on May 26, 2020 3:37pm
176 Views
Post# 31074663

Let's Hope The Price Is Right !

Let's Hope The Price Is Right !Truth is my hand has been floating above the sell button steady since the stero deal fiasco.... at xmas when dates were pushed out to March I thought there was a solid offer just getting finalized... after the NR re Stero I was like WTF ... I considered Stero to have some value but not enough for Kly to buy in the position we were and felt like there had to be more to it...then Kly cancelled and dates pushed out again..I realized that Kly had nothing concrete but we still had our GVHD ..the sp shot down to 1 cent ...when the NR came re buying Salzman Group ... I saw much greater value added with the factors of having possible govt funding and on the covid wagon...I couldn't ignore then that our GVHD was in jeopardy and I knew that Kly needed to address that with us... I thought the only way for Kly to proceed with the acquisition with all shares that money has to come from somewhere to keep investors interest ... that's why I was anticipating update on GVHD ... I just hope that we get a favorable price ..or anything is better... rather then Talent get it back for nothing and almost finished ... again I repeat if the science is true of what was published there are pharmas that are interested ... only reason I am holding ...glta
<< Previous
Bullboard Posts
Next >>